News

IDT Australia Limited (ASX: IDT) provides the following market update that it has entered into a manufacturing agreement with Cann Group Limited (ASX: CAN). IDT has been contracted to provide manufacturing support in relation to medicinal cannabis‐based product formulations intended for supply to patients in Australia and overseas. “Cann Group has established itself as an…

IDT Australia Limited (IDT) provides the following market update regarding the meeting held with the U.S. Food and Drug Administration (FDA) in Washington on 24 July 2018. Ms Michelle Coffey and Dr David Sparling, along with IDT’s U.S. based specialist consultants today attended a meeting with representatives from the FDA’s Office of Manufacturing Quality. The…

In keeping with the Company’s recently announced Generics Strategy, whereby IDT is to advance a selected generics portfolio and to build on the Company’s existing Commercial API and Contract Manufacturing businesses, IDT Australia has divested a majority of the Company’s generic ANDA product portfolio to ANI Pharmaceuticals Inc. Under the terms of the divestment, IDT…

IDT Australia Limited (IDT) announces the appointment of Dr David Sparling as interim Chief Executive Officer. Dr Sparling is currently Vice President of Corporate & Business Development at IDT and brings a wealth of experience in the pharmaceutical industry to the role.

The Executive Chairman of IDT, Mr Graeme Kaufman, has advised that he is standing down from the position of Chairman with effect from today.  Mr Kaufman will continue as a Director and will continue in his interim executive role. The Board has appointed Mr Alan Fisher as Chairman.  Mr Fisher has extensive business and corporate experience and…

Australian pharmaceutical manufacturing and drug development company IDT Australia Limited (ASX: IDT) announces it has executed an Active Pharmaceutical Ingredient (API) Development Agreement with The State Government of Victoria (Victorian Government). The exact details of both the API and the commercial terms are confidential between IDT and the Victorian Government, however the agreement extends for…

Australian pharmaceutical manufacturing and drug development company IDT Australia Limited (ASX: IDT) announces the final completion of the staged divestment of its CMAX clinical trial business to Japanese integrated healthcare company I’rom Group Co., Ltd (I’rom). IDT confirmsreceipt of $6,159,892 in cash for IDT’sremaining 39% stake in the CMAX business.  The final consideration payment increased from…

IDT Australia has today launched a newly responsive website created for use across mobile, tablet and desktop technologies. Retaining a quick “go-to” breakout investor section, the new site uses banner imagery and video to better showcase IDT’s award-winning API and ready for market manufacturing capabilities. “The IDT business continues to evolve, and today we offer…

The Managing Director of IDT, Dr Paul MacLeman has resigned from the position, to advance new business initiatives and to pursue further non‐executive board roles. His resignation as CEO will take effect from 31st August 2017. Dr MacLeman will resign from the Board as at close of business today. The Chairman, Mr Graeme Kaufman, thanked…

Australian pharmaceutical manufacturing and drug development company IDT Australia Limited (ASX: IDT) announces the retirement of our founder, Dr Graeme Blackman AO, from the Board.  Dr Blackman will remain an advisor to the Company.